Aileron's gets another $33M to begin trials of cancer drug within weeks

Aileron Therapeutics has gotten another $33 million of funding, bringing the 9-year-old biotech's total to well over $100 million, and appointed two new executives to help bring its second drug in development to clinical trials in coming weeks...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.